Vivek Ramnani, Managing Director of Eurocor Tech GmbH, commented: “We are very excited to add this product to our portfolio. Eurolimus will prove to be a highly efficient addition to the coronary interventionist’s tool set. We are proud to offer a product with excellent performance and security profile while achieving one of the longest shelf-life in the industry.”
Eurolimus has proven to have excellent efficacy and safety within two European clinical studies with two year follow up showing extremely low rates of stent thrombosis. The Drug release covers the entire restenotic cascade to ensure proper vessel healing.
Eurocor Tech GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.
On Wednesday early trade, Opto Circuits (India) was trading at Rs4.40 per piece up by Rs0.06 or 1.38% on Sensex.